# CURRICULUM VITAE


**Name:** Morteza Pourfarzam

**Work Address:** Department of Clinical Biochemistry
Faculty of Pharmacy
Isfahan University of Medical sciences
Isfahan, Iran, 81746-73461

**Email:** morteza.pourfarzam@yahoo.com

**Telephone (Office):** 0313 7927045
**Mobile:** 0913 2709408


## EDUCATION

**1991-1995** Post-doctoral
Pediatric Clinical Biochemistry and Inborn errors of Metabolism
University of Newcastle upon Tyne, ENGLAND

**1987-1991** PhD (Clinical Biochemistry)
University of Newcastle upon Tyne, ENGLAND

**1986-1987** MSc (Clinical Biochemistry)
University of Newcastle upon Tyne, ENGLAND

**1980-1984** BSc (Chemistry)
University of Isfahan, Iran

## ACADEMIC APPOINTMENTS:

### PRESENT APPOINTMENT

**2017-present** Professor – Scale 26
Department of Clinical Biochemistry
School of Pharmacy
Isfahan University of Medical Sciences

### PAST APPOINTMENTS

**2011-2017** Associate Professor
Department of Clinical Biochemistry
School of Pharmacy
Isfahan University of Medical Sciences

**2009-2011** Assistant Professor
Department of Clinical Biochemistry
School of Pharmacy

| | |
|---|---|
| | Isfahan University of Medical Sciences |
| **2004-2008** | Consultant Clinical Biochemist and Deputy Director of Newcastle Newborn Screening program<br>The Newcastle upon Tyne Hospitals NHS Trust<br>Newcastle upon Tyne, England<br>and<br>Senior lecturer in Paediatric Biochemistry<br>School of Clinical Medical Sciences<br>University of Newcastle upon Tyne |
| **1996- 2008** | Director of Spence biochemical genetics Unit<br>University of Newcastle upon Tyne<br>Newcastle upon Tyne, |
| **1996- 2004** | Lecturer in Paediatric Biochemistry<br>School of Clinical Medical Sciences<br>University of Newcastle upon Tyne and<br>Newcastle upon Tyne, England |
| **1995-1996** | Lecturer<br>Departments of Child Health and<br>Clinical Neurosciences<br>University of Newcastle upon Tyne<br>England |
| **1991-1995** | Post-doctoral research associate<br>Departments of Child Health and<br>Clinical Neurosciences<br>University of Newcastle upon Tyne<br>England |

## EXECUTIVE & ADMINISTRATIVE APPOINTMENTS:

| | |
|---|---|
| **2018-Present** | Sub-Dean for Research Centers<br>School of Pharmacy<br>Isfahan University of Medical Sciences<br>Isfahan, Iran |
| **2017-2018** | Director for Research<br>Isfahan University of Medical Sciences<br>Isfahan, Iran |
| **2016-2017** | Executive Director<br>Vice Chancellery for Research<br>Isfahan University of Medical Sciences<br>Isfahan, Iran |
| **2015-2016** | Director<br>Bureau for Scientific & International Affairs |

Isfahan University of Medical Sciences
Isfahan, Iran

**2004-2008** Deputy Director of Newcastle Newborn Screening program
The Newcastle upon Tyne Hospitals NHS Trust
Newcastle upon Tyne, England

**1996- 2008** Director of Spence biochemical genetics Unit
University of Newcastle upon Tyne
Newcastle upon Tyne

## PROFESSIONAL QUALIFICATIONS

| | |
|---|---|
| Fellow of the Royal college of Pathologist **(MRCPath)** | 2003 |
| Fellow of the Royal College of Paediatrics and Child Health **(FRCPCH)** | 2002 |
| European Specialist in Clin Chem and Lab Medicine **(EurClinChem)** | 2012 |

## PROFESSIONAL MEMBERSHIP

Member of the Association of Clinical Biochemists
Member of the Society for study of Inborn Errors of Metabolism (SSIEM)

## TEACHING

MSc Clinical Biochemistry, MSc Biomedical Sciences, MSc Biotechnology
PhD Clin Biochem, PhD Medicinal Chemistry, PhD Nutrition
MBBS, Pharm D

## PAST RESEARCH SUPERVISION:

More than 20 undergarduate students
10 MSc students
10 PhD students

**STUDENTS CURRENTLY UNDER SUPERVISON:**
4 PhD Students
2 MSc Students

# PUBLICATIONS

1) **Pourfarzam, M**, Naughten E, Cahalane S, Bhuiyan AKMJ and Bartlett K.
*Measurment of plasma octanoate in sudden infant death syndrome using a stable isotope dilution assay.*
In "Stable isotopes in paediatrics nutritional and metabolic research" (Chapman, TE, Berger, R, Reijngoud, DJ and Okken, A. eds.) Intercept, U.K. 1990, pp 249-255.

2) **Pourfarzam M** and Bartlett K.
*Products and intermediates of the ß-oxidation of [U-$^{14}$C]hexadecanedioyl-mono-CoA by rat liver peroxisomes and mitochondria.*
Biochem. J. (1991) **273**: 205-210

3) **Pourfarzam M** and Bartlett K.
*Synthesis, characterisation and high-performance liquid chromatography of $C_6$-$C_{16}$ dicarboxylyl-mono-coenzyme A and -mono-carnitine esters.*
J. Chromatogr. (1991) **570**: 253-276

4) Singh Kler R, Jackson S, Bartlett K, Bindoff L, **Pourfarzam M**, Frerman FE, Goodman SI, Watmough NJ and Turnbull DM.
*Quantitation of Acyl-CoA and Acyl-carnitine esters accumulated during abnormal mitochondrial fatty acid oxidation.*
J. Biol. Chem. (1991) **266**: 22932-22938.

5) **Pourfarzam M.** and Bartlett K.
*Intermediates of peroxisomal ß-oxidation of [U-$^{14}$C]hexadecanedionoate: A study of the acyl- CoA esters which accumulateduringperoxisomal ß-oxidation of [U-$^{14}$C]hexadecanedionoate and [U-$^{14}$C]hexadecanedioyl-mono-CoA.*
Eur. J. Biochem. (1992) **208**: 301-307.

6) Jackson S, Singh Kler R, Bartlett K, Briggs H, Bindoff L A, **Pourfarzam M**, Gardner-Medwin D and Turnbull DM.
*Combined enzyme defect of mitochondrial fatty acid oxidation .*
J. Clin. Invest. (1992) **90**: 1219-1225.

7) Taylor RW, Jakson S, **Pourfarzam M** , Bartlett K and Turnbull DM.
*Measurment of Acyl-CoA dehydrogenase activity in cultured skin fibroblasts and blood platelets.*
J. Inher. Metab. Dis. (1992) **15**: 727-732.

8) Jackson S, Singh Kler R, Bartlett K, **Pourfarzam M**, Aynsley-Green A, Bindoff LA and Turnbull DM.
*Combined defect of long-chain 3-hydroxyacyl-CoA dehydrogenase, 2-enoyl-CoA hydratase and 3-oxoacyl-CoA thiolase.*
*In* Fatty Acid Oxidation: Clinical, Biochemical and Molecular Aspects. K Tanaka and P M Coates, editors. Wiley-Liss, New York. 1992, pp 327-337.

9) **Pourfarzam M** and Bartlett K.
*Skeletal muscle ß-Oxidation of dicarboxylates.*
Biochim. Biophys. Acta, (1993) **1141**: 81-89.

10) Ogilvie I, **Pourfarzam M**, Jackson S, Stockdale C, Bartlett K and Turnbull DM.
*Very long-chain acyl-CoA dehydrogenase deficiency presenting with exercise-induced myoglobinura.*
Neurology, (1994) **44**: 467-473.

11) Osmundsen H, Hovik R, Bartlett K and **Pourfarzam M.**
*Regulation of flux of acyl-CoA esters through peroxisomal ß-oxidation*
Biochem. Soc. Trans. (1994) **22**: 436-441.

12) Morris AAM, Deshpande S, Ward-Platt MP, Whitfield AE, Aynsley-Green A, Leonard JV, **Pourfarzam M** and Bartlett K.
*Impaired ketogenesis in fructose-1,6-bisphosphatase deficiency: a pitfall in the investigation of hypoglycaemia.*
J. Inher. Metab. Dis. (1995) **18**: 28-32.

13) **Pourfarzam M**, Schaefer J, Turnbull DM and Bartlett K.
*Analysis of fatty acid oxidation intermediates in cultured fibroblasts to detect mitochondrial oxidation disorders.*
Clin. Chem. (1995) **40**: 2267-2275.

14) Schaefer J, **Pourfarzam M**, Jackson S, Bartlett K and Turnbull DM.
*Fatty acid oxidation in peripheral blood cells: characterisation and use for the diagnosis of defects of fatty acid oxidation.*
Pediatr. Res. (1995) **37**: 354-360.

15) Sleboda J, **Pourfarzam M**, Bartlett K and Osmundsen H.
*Effects of added L-carnitine, acetyl-CoA and CoA on peroxisomal ß-oxidation of [U-$^{14}$C]hexadecanoate* by *isolated peroxisomal fractions.*
Bichim. Biophys. Acta, (1995) **1258**: 309-318.

16) Ogier de Baulny H, Salma A, Touati G, Turnbull DM, **Pourfarzam M** and Brivet M.
*Neonatal hyperammonemia caused by a defect of carnitine-acylcarnitine translocase.*
J. Pediatr (1995) **127**: 723-8.

17) Eaton SJ, **Pourfarzam M** and Bartlett K.
*The effect of respiratory chain impairment on β-oxidation in rat heart mitochondria.*
Biochem. J. (1996) **319**: 633-640.

18) Eaton SJ, Bartlett K and **Pourfarzam M.**
*Mammalian mitochondrial β-oxidation.*
Biochem. J. (1996) **320**: 345-357.

19) Osmundsen H, Bartlett K, **Pourfarzam M**, Eaton SJ, and Sleboda J.
*Substrate Channelling in β-oxidation: myth or reality?*
In: Agius L, Sherratt HSA eds. Channelling in intermediary metabolism. London: Portland press, 1997: 293-313.

20) Bartlett K and **Pourfarzam M.**
*Inherited disorders of mitochondrial fatty acid oxidation.*
Current Paed. (1997) **7**: 118-122.

21) **Pourfarzam M** and Bartlett K.
*The Synthesis, purification and characterisation of dicarboylyl-mono-coenzyme A esters.*
Methods Enzymol. (1997) **279**: 240-254.

22) Bartlett K, Eaton SJ and **Pourfarzam M.**
*New Developments in Neonatal Screening .*
Arch. Dis. Child. (1997) **77**: F151-F154.

23) Moore SJ, Haites NE, Broom I, White I, Coleman R, **Pourfarzam M** and Morris AAM.
*Acylcarnitine analysis in the investigation of myopathy*
J. Inher. Metab. Dis. (1998) **21**: 427-428.

24) Bartlett K and **Pourfarzam M.**
*Recent Developments in the detection of inherited disorders of mitochondrial β-oxidation.*
Biochem. Soc. Trans. (1998) **26**: 145-152.

25) AAM Morris, SWJ Richmond, SJ Oddie, **M Pourfarzam**, V Worthington and JV Leonard.
*N-Acetylglutamate synthetase deficiency: Favourable experience with carbamylglutamate.*
J. Inher. Metab. Dis. (1998) **21**: 867-868.

26) Manning NJ, JR Bonham, M Downing , RG Edwards, SE Olpin, RJ Pollitt, **M Pourfarzam**, MJ Sharrard and MS Tanner
*Normal acylcarnitines in maternal urine during a pregnancy affected by glutaric aciduria type II.*
J. Inher. Metab. Dis. (1999) **22**: 88-89.

27) Eaton S, K Bartlett , **M Pourfarzam**
*Intermediates Of Myocardial Mitochondrial β-Oxidation: Possible Channelling Of NADH and of CoA esters*
Biochim Biophysica Acta (1999) **1437**: 402-408.

28) Andresen BS, S Olpin, B Poorthuis, HR Scholte, C Vianey-Saban, R Wanders, L Ijlst, A Morris, **M Pourfarzam**, K Bartlett, R Baumgartner, JBC deKlerk, LD Schroeder, TJ Corydon, H Lund, V Winter, P Bross, L Bolund, N Gregersen.
*Clear correlation of genotype with disease phenotype in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency.*
Am. J. Hum. Gen. (1999) **64**: 479-494.

29) Bartlett K, **Pourfarzam M**
*Tandem Mass Spectrometry-The potential*
J. Inher. Metab. Dis. (1999) **22**: 568-571.

30) Eaton S. Bartlett K. **Pourfarzam M**. Markley MA. New KJ. Quant PA.
*Production and export of acylcarnitine esters by neonatal rat hepatocytes.*
dvances in Experimental Medicine & Biology. (1999) **466**: 155-9.

31) Eaton S. Middleton B. Sherratt HS. **Pourfarzam M**. Quant PA. Bartlett K.
*Control of mitochondrial beta-oxidation at the levels of [NAD+]/[NADH] and CoA acylation.*
Advances in Experimental Medicine & Biology. (1999) **466**: 145-54.

32) Eaton S. Skinner R. Hale JP. **Pourfarzam M**. Roberts A. Price L. Bartlett K.
*Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy.* Clinica Chimica Acta. (2000) **302**(1-2): 1-9.

33) Eaton S. Bursby T. Middleton B. **Pourfarzam M**. Mills K. Johnson AW. Bartlett K.
*The mitochondrial trifunctional protein: centre of a beta-oxidation metabolon?*
Biochemical Society Transactions. (2000) **28**(2): 177-82.

34) Osorio-Orozco JH. **Pourfarzam M.**
*Diagnostic error of mental retardation of neurometabolic origin confirmed by mass sequential spectrometry.*
Revista de Neurologia. *(2000)* ***30****: 728-30..*

35) **Pourfarzam M**, Morris A, Appleton M, Craft A, Bartlett K.
Neonatal screening for medium-chain acyl-CoA deghydrogenase deficiency.
Lancet (2001) **358**: 1063-1064.

36) Tyni T, Johnson M, Eaton S, **Pourfarzam M**, Andrews R, Turnbull DM
*Mitochondrial fatty acid beta-oxidation in the retinal pigment epithelium.*
Pediat Res (2002) **52**: 595-600.

37) Tyni T, **Pourfarzam M**, Turnbull DM
*Analysis of mitochondrial fatty acid oxidation intermediates by tandem mass spectrometry from intact mitochondria prepared from homogenates of cultured fibroblasts, skeletal muscle cells, and fresh muscle.*
Pediat Res (2002) **52**: 64-70.

38) Osorio JH, **Pourfarzam M**
*Plasma free and total carnitine measured in children by tandem mass spectrometry.*
Braz J Med Biol Res (2002) **35**: 1265-1271.

39) Bartlett K, **Pourfarzam M**
*Defects of β-oxidation including carnitine deficiency.*
International Review of Neurobiology (2002) **53**: 471-517.

40) Deschauer M, Chrzanwska-Lightowlers ZMA, Bieckmann E, **Pourfarzam M**, Taylor RW, Turnbull DMT and Zierz S.
*A splice junction mutation in muscle carnitine palmitoyltransferase II deficiency.*
Mol. Genet. Metab. (2003) **79**: 124 - 128.

41) Kölker S, Hoffmann GF, Schor DS, Feyh P, Wagner L, Jeffrey I, **Pourfarzam M**, Okun JG, Zschocke J, Baric I, Bain MD, Jakobs C, Chalmers RA
*Glutaryl-CoA dehydrogenase deficiency: region-specific analysis of organic acids and acylcarnitines in post mortem brain predicts vulnerability of the putamen.*
Neuropediatrics (2003) **34**: 253-60

42) Olpin SE, Afifi A, Clark S, Manning NJ, Bonham JR, Dalton A, Leonard JV, Land JM, Andresen BS, Morris AA, Muntoni F, Turnbull D, **Pourfarzam M**, Rahman S, Pollitt RJ.
*Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency.*
J. Inher. Metab. Dis. (2003) **26**: 543-557.

43) Osorio-Orozco JH. **Pourfarzam M.**
*Early diagnosis of neurometabolic disease by tandem mass spectrometry. Acylcarnitine profile from cord blood.*
Revista de Neurologia. (2004) **38**:11-16.

44) Olsen RKJ, **Pourfarzam M**, Morris AAM, Dias RC, Knudsen I, Andresen BS, Gregersen N, Olpin SE
*Lipid storage myopathy and respiratory insufficiency due to ETFQO mutations in a patient with late-onset multiple acyl-CoA dehydrogenase deficiency.*
J. Inher. Metab. Dis. (2004) **27**: 671-678.

45) Olpin SE, Clark S, Andresen B, Bischoff C, Olsen RKJ, Gregersen N, Chakrapani A, Downing M, Manning NJ, Sharrard M, Bonham JR, Muntoni F, Turnbull DM, **Pourfarzam M**
*Biochemical, clinical and molecular findings in LCHAD and general mitochondrial trifunctional protein deficiency.*
J. Inher. Metab. Dis. (2005) **28**: 533-544.

46) Beresford MW, **Pourfarzam M**, Turnbull DM, Davidson JE
*So doctor, what exactly is wrong with my muscles? Glutaric aciduria type II presenting in a teenager.*
Neuromuscul Disord. (2006) **16**(4):269-73.

47) Olsen RKJ, Olpin SE, Andresen B, Miedzybrodzka ZH, **Pourfarzam** M, Merino B, Frerman FE, Beresford MW, Dean JCS, Cornelius N, Andersen O, Oldfors A, Holmes E, Gregersen N, Turnbull DM and Morris AAM.
*ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.*

Brain (2007), **130**, 2045 – 2054.

48) Osorio JH, **Pourfarzam M**.
*Determination of normal acylcarnitine levels in a healthy pediatric population as a diagnostic tool in inherited errors of mitochondrial fatty acid beta-oxidation.*
An Pediatr (Barc). (2007); **67**(6):548-52.

49) Merinero B, Pérez B, Pérez-Cerdá C, Rincón A, Desviat LR, Martínez MA, Sala PR, García MJ, Aldamiz-Echevarría L, Campos J, Cornejo V, Del Toro M, Mahfoud A, Martínez-Pardo M, Parini R, Pedrón C, Peña-Quintana L, Pérez M, **Pourfarzam M**, Ugarte M.
*Methylmalonic acidaemia: examination of genotype and biochemical data in 32 patients belonging to mut, cblA or cblB complementation group.*
J. Inher. Metab. Dis. (2008) **31**(1):55-66.

50) McGarry K, Bartlett K, **Pourfarzam M**
*Exploratory data analysis for investigating GC-MS biomarkers*
Lecture notes in computer science (2008); Vol **5265** LNBI: 349-358

51) Henry Osorio Jose; **Pourfarzam Morteza**
*Hydrolysis of acylcarnitines during measurement in blood and plasma by tandem mass spectrometry* ACTA BIOQUIMICA CLINICA LATINO AMERICANA (2010), Volume: 44 Issue: 2 Pages: 189-193.

52) Henry Osorio Jose; **Pourfarzam Morteza**
*Levels of carnitine and acylcarnitines in reconstituted red blood cell samples washed with different concentrations of saline solutions*
COLOMBIA MEDICA (2010), Volume: 41 Issue: 4 Pages: 344-348

53) Hajhashemi, V; Vaseghi, G; **Pourfarzam**, M; Abdollahi, A
*Are antioxidants helpful for disease prevention?*
RESEARCH IN PHARMACEUTICAL SCIENCES (2010) Volume: 5 Issue: 1 Pages: 1-8

54) Basati, Gholam; **Pourfarzam, Morteza**; Movahedian, Ahmad; Samsamshariat, Saed Ziaaldin; Sarrafzadegan, Nizal
*Reduced plasma adiponectin levels relative to oxidized low density lipoprotein and nitric oxide in coronary artery disease patients*
CLINICS (2011) Volume: 66 Issue: 7 Pages: 1129-1135 DOI: 10.1590/S1807-59322011000700002

55) Samsamshariat, Saedziaaldin; Basati, Gholam; Movahedian, Ahmad; **Pourfarzam, Morteza**; Sarrafzadegan, Nizal
*Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease*
JOURNAL OF RESEARCH IN MEDICAL SCIENCES (2011); Volume: 16 Issue: 5 Pages: 674-679.

56) Samsamshariat, Saed Ziaaldin; Basati, Gholam; Movahedian, Ahmad; **Pourfarzam, Morteza**; Sarrafzadegan, Nizal.
*Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease*
BIOMARKERS IN MEDICINE (2011 ), Volume: 5 Issue: 3 Pages: 377-385 DOI: 10.2217/BMM.11.28

57) Amirnader Emami Razavi, Mohsen Ani. **Morteza Pourfarzam**, Gholam Ali Naderi
*Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity*
JOURNAL OF RESEARCH IN MEDICAL SCIENCES (2012), Vol 17, No 11; Pages 1020-1026.

58) Lotfollah Saghaie, **Morteza Pourfarzam**, Afshin Fassihi, Behzad Sartippour.
*Synthesis and tyrosinase inhibitory properties of some novel derivatives of kojic acid.*

RESEARCH IN PHARMACEUTICAL SCIENCES (2013) Volume: 8, Issue: 4, Pages: 233-242.

59) Amirnader Emami Razavi, Mohsen Ani. **Morteza Pourfarzam**, Gholam Ali Naderi.
*The associations between high density lipoprotein mean particle size and its fatty acid composition.*
BIOMARKERS IN MEDICINE (2013) Volume: 7(2):235-45. doi: 10.2217/bmm.12.115.

60) **Morteza Pourfarzam**, Ahmad Movahedian, Nizal Sarrafzadegan, Gholam Basati, Saed Ziaaldin Samsamshariat.
*Association between Plasma Myeloperoxidase and Free 3-Nitrotyrosine Levels in Patients with Coronary Artery Disease.*
International Journal of Clinical Medicine (2013) 4, 158-164, doi:10.4236/ijcm.2013.43028.

61) **Morteza Pourfarzam** , Bahara Barati.
*The Necessity of Screening of Individuals with Suspected Inherited Metabolic Disorders for Early Diagnosis and Treatment of Related Diseases.*
Journal of Isfahan Medical School (2013) Vol. 30, No. 221, Pages 2493-2505.

مرتضی پورفرزام، بهارا براتی
**ضرورت انجام تست های غربالگری در بیماران مشکوک به اختلالات ارثی متابولیسم برای تشخیص و درمان زود هنگام بیماری.** مجله دانشکده پزشکی اصفهان ۱۳۹۱: ۳۰(۲۲۱): ۲۵۰۵- ۲۴۹۳

62) Abdolamir Atapour, Hamid Mir-Mohammad Sadeghi, Khadijeh Mahboobnia, **Morteza Pourfarzam.**
*Correlation between Serum Parathyroid Hormone and Markers of Bone Metabolism in Hemodialysis Patients*.
Journal of Isfahan Medical School (2013) Vol. 31, No. 244, Pages 1059-1066**.**

عبدالامیر عطاپور، حمید میرمحمد صادقی، خدیجه محبوب نیا، مرتضی پورفرزام.
**ارتباط بین سطح سرمی هورمون پاراتیروئید با مارکرهای متابولیسم استخوان در بیماران همودیالیزی**. مجله دانشکده پزشکی اصفهان۱۳۹۲: ۳۱(۲۴۴): ۱۰۶۶- ۱۰۵۹

63) **Morteza Pourfarzam,** Fouzieh Zadhoush
*Newborn Screening for inherited metabolic disorders; news and views.*
JOURNAL OF RESEARCH IN MEDICAL SCIENCES (2013), vol 18, No. 9; pages: 801-808.

64) Shahlaei M, Fassihi A, Papaleo E, **Pourfarzam M.**
*Molecular Dynamics Simulation of Chemokine Receptors in Lipid Bilayer: A Case Study on C-C Chemokine Receptor Type 2.*
Chemical Biology & Drug Design 2013; August . doi: 10.1111/cbdd.12179

**65)** M Boshtam, A Emami Razavi, M Pourfarzam, M Ani, GA Naderi, G Basati, M Mansourian, N Jafari Dinani, S Asgary, S Abdi**.**
*Serum Paraoxonase 1 Activity Is Associated with Fatty Acid Composition of High Density Lipoprotein*
Disease Markers (2013), 35(4), Pages: 273–280

66) Azam Dadkhah, Mahin Hashemipour, Afshin Fassihi, Bahara Barati, **Morteza Pourfarzam.**
*Establishment of Reference Ranges and Profile of Urinary Organic Acids in Different Pediatric Age Groups of the Iranian Healthy Population.*
Journal of Isfahan Medical School (2014) Vol. 32, No. 280, Pages 1-15**.**

اعظم دادخواه، مهین هاشمی پور ،افشین فصیحی ، بهارا براتی ، مرتضی پورفرزام.
**تعیین محدوده ی طبیعی و پروفایل ارگانیک اسیدهای ادرار در رده های سنی مختلف کودکان سالم ایران.** مجله دانشکده پزشکی اصفهان ۱۳۹۳: ۳۲(۲۸۰): ۱-۱۵

67) Gholamreza Namazi, **Morteza Pourfarzam**, Sabieh Jamshidi Rad, Ahmad Movahedian Attar, Nizal Sarrafzadegan, Masoumeh Sadeghi, and Parastoo Asa.
*Association of the Total Cholesterol Content of Erythrocyte Membranes with the Severity of Disease in Stable Coronary Artery Disease.*
Cholesterol (2014), Article ID 821686, 6 pages

68) Gholamreza Namazi , Sabieh Jamshidi Rad , Ahmad M Attar, Nizal Sarrafzadegan, Masoumeh Sadeghie, Gholamali Naderi and **Morteza Pourfarzam.**
*Increased membrane lipid peroxidation and decreased Na +/K+-ATPase activity in erythrocytes of patients with stable coronary artery disease.*
Coronary Artery Disease. 26(3):239-244, May 2015. **doi: 10.1097/MCA.0000000000000196**

69) Fouzieh Zadhoush, Masoumeh Sadeghi, **Morteza Pourfarzam**
*Biochemical changes in blood of type 2 diabetes with and without metabolic syndrome and their association with metabolic syndrome components*
JOURNAL OF RESEARCH IN MEDICAL SCIENCES. (2015), 20:763-70

70) Asadzadeh, A., Fassihi, A., Yaghmaei, P., **Pourfarzam, M.**
*Docking studies of some novel Kojic acid Derivatives as possible tyrosinase inhibitors.*
Biomedical and Pharmacology Journal. 2015, 8(2), 535-545.

71) Asadzadeh, A, Fassihi, A, Yaghmaei, P, **Pourfarzam, M**.
*In silico approach for designing potent inhibitors against tyrosinase.*
Biosciences Biotechnology Research Asia. 2015, 12, 181-187 .

72) A Asadzadeh, H Sirous, **Morteza Pourfarzam**, P Yaghmaei, A Fassihi .
*In vitro and in silico studies of the inhibitory effects of some novel kojic acid derivatives on tyrosinase enzyme .*
Iranian Journal of Basic Medical Sciences. 2016, 19(2), 132-144.

73) **Morteza Pourfarzam**, Fouzieh Zadhoush, Masoumeh Sadeghi.
*The difference in correlation between insulin resistance index and chronic inflammation in type 2 diabetes with and without metabolic syndrome.*
Adv Biomed Res 2016;5:153

74) Gholamreza Namazi, Parastoo Asa, Ahmad Movahedian, Nizal Sarrafzadegan, Masoumeh Sadeghi and **Morteza Pourfarzam**.
*Investigation of membrane fatty acid profiles in erythrocytes of patients with stable coronary artery disease.*
Journal of Clinical Lipidology. 2016, 10(4), 930-936

75) Ebrahimi M, Rouzbahani R, **Pourfarzam M**. Reporting 7 Pompe Patients in Iran. J Isfahan Med Sch 2017; 35(424): 364-7.

میلاد ابراهیمی، رضا روز بهانی، مرتضی پورفرزام.
**گزارش ۷ مورد بیماری** Pompe **در ایران.** مجله دانشکده پزشکی اصفهان ۱۳۹۶: ۳۵(۴۲۴): ۳۶۴-۷

76) Leila Mazoochian, Hamid Mir Mohammad Sadeghi, **Morteza Pourfarzam**. *The effect of FADS2 gene rs174583 polymorphism on desaturase activities, fatty acid profile, insulin resistance, biochemical indices, and incidence of type 2 diabetes.*
JOURNAL OF RESEARCH IN MEDICAL SCIENCES. (2018), 2018; 23: 47. doi: 10.4103/jrms.JRMS_961_17.

77) Namazi G, Asa P, Sarrafzadegan N, **Pourfarzam M**.
Decreased Na+/K+-ATPase Activity and Altered Susceptibility to Peroxidation and Lipid Composition in the Erythrocytes of Metabolic Syndrome Patients with Coronary Artery Disease.
Ann Nutr Metab. 2019 Feb 7;74(2):140-148. doi: 10.1159/000497065. [Epub ahead of print]

78) Hayatmoghadam B, Zadhoush F, Amirkhani F, **Pourfarzam M**.

*Cholesterol Synthesis and Absorption Markers in Type 2 Diabetes Mellitus.*
J Isfahan Med Sch 2019; 37(519): 214-21.

حیات مقدم بنت الهدی، زادهوش فوزیه، امیرخانی فهیمه، پورفرزام مرتضی. **بررسی نشانگرهای سنتز و جذب کلسترول در بیماری دیابت نوع ۲**
مجله دانشکده پزشکی اصفهان ۱۳۹۸: ۳۷(۵۱۹): ۲۱۴-۲۲۱

79) Amirkhani F, Namazi G, Hayatmoghadam B, **Pourfarzam M**.
*Evaluation of Cholesterol Synthesis and Absorption Pathways in Patients with Cardiovascular Diseases.*
J Isfahan Med Sch 2019; 37(523): 385-91.

امیرخانی فهیمه، نمازی غلامرضا، حیات مقدم بنت الهدی، پورفرزام مرتضی. **بررسی مسیرهای جذب و سنتز کلسترول در بیماران قلبی-عروقی.**
مجله دانشکده پزشکی اصفهان ۱۳۹۸: ۳۷(۵۲۳): ۳۸۵-۳۹۱

80) Hooria Seyedhosseini Ghaheh, Mohamad Reza Ganjalikhany, Parichehreh Yaghmaei, **Morteza Pourfarzam**, and Hamid Mir Mohammad Sadeghi. *Improving the solubility, activity, and stability of reteplase using in silico design of new variants.*
Res Pharm Sci. 2019 Aug; 14(4): 359–368. doi: 10.4103/1735-5362.263560: 10.4103/1735-5362.263560.

81) Hooria Seyedhosseini Ghaheh, Mohamad Reza Ganjalikhany, Parichehreh Yaghmaei, **Morteza Pourfarzam**, and Hamid Mir Mohammad Sadeghi. *Investigation of Supercharging as A Strategy to Enhance the Solubility and Plasminogen Cleavage Activity of Reteplase.* Iranian J Biotech. October 2020;18(4): e2556DOI: 10.30498/IJB.2020.2556

82) Negar Dinarvand, Hossein Khanahmad,Sayyed Mohammadreza Hakimian, Abdolkarim Sheikhi Bahman Rashidi, Hadi Bakhtiari, **Morteza Pourfarzam**. *Expression and clinicopathological significance of lipin-1 in human breast cancer and its association with p53 tumor suppressor gene.*
J Cell Physiol. 2020: 1-12. https://doi.org/10.1002/jcp.29523.

83) Negar Dinarvand, Hossein Khanahmad, Sayyed Mohammadreza Hakimian, Abdolkarim Sheikhi, Bahman Rashidi, and **Morteza Pourfarzam**. *Evaluation of long-chain acyl-coenzyme A synthetase 4 (ACSL4) expression in human breast cancer.* Res Pharm Sci. 2020 Jan; 15(1).

84) Khodadadi, M., **Pourfarzam, M**. *A review of strategies for untargeted urinary metabolomic analysis using gas chromatography–mass spectrometry.* Metabolomics 16, 66 (2020). https://doi.org/10.1007/s11306-020-01687-x

85) Gholamreza Namazia, Raziyeh Salami, **Morteza Pourfarzam**, Parastoo Asa, Alireza Mafi, Fariba Raygan. *Association of the serum apelin, but not ghrelin, with the presence and severity of coronary artery disease.* Indian Heart Journal (Jan 2021).
https://doi.org/10.1016/j.ihj.2021.01.013

86) Najaf Ali, **Pourfarzam Morteza**, Zadhoush Fouzieh. *Oxidant/antioxidant status in Type-2 diabetes mellitus patients with metabolic syndrome.* J Res Med Sci 2021;26:6. DOI: 10.4103/jrms.JRMS_249_20.

87) Mehdi Zobeiri, Fatemeh Parvizi, Zahra Shahpiri, Fatemeh Heydarpour, **Morteza Pourfarzam**, Mohammad Reza Memarzadeh, Roja Rahimi, and Mohammad Hosein Farzae

*Evaluation of the Effectiveness of Cinnamon Oil Soft Capsule in Patients with Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Clinical Trial,"* Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 6634115, 7 pages, 2021. https://doi.org/10.1155/2021/6634115.

88) Amin Omidian, **Morteza Pourfarzam**, Seyed Mostafa Ghanadian, and Fouzieh Zadhoush. *Determination of plasma and erythrocyte levels of copper, magnesium and zinc by atomic absorption spectrometry in type-2 diabetes mellitus patients with metabolic syndrome*. Res Pharm Sci. 2022 Feb; 17(1): 86-98. DOI: 10.4103/1735-5362.329929.

89) Fatemeh Masoudi, Mohammad Reza Sharifi, and **Morteza Pourfarzam.** *Investigation of the relationship between miR-33a, miR-122, erythrocyte membrane fatty acids profile, and serum lipids with components of metabolic syndrome in type 2 diabetic patients.* Res Pharm Sci. 2022 June; 17(3): 242-251. DOI: 10.4103/1735-5362.343078.

## **Abstracts**:

1) Henderson MJ, Evans CE, Kumar V and **Pourfarzam M**.
*Malonic aciduria presenting with developmental delay, malonylcarnitine increased in blood spots.*
J. Inher. Metab. Dis. (1998) 21, Suppl. 2: 53.

2) Kirk JM, Fitzpatrick D, Olpin S, Downing M, Storstein Andressen B, Gregersen N and **Pourfarzam M**.
*An atypical case of Medium-Chain Acyl-CoA Dehydrogenase Deficiency.*
J. Inher. Metab. Dis. (1998) 21, Suppl. 2: 67.

3) Singh-Kler R, S Jakson, **M Pourfarzam**, AAM Morris, J Shaefer and DMT Turnbull.
*Clinical features, investigation and management of adult patients with defects of mitochondrial fatty acid oxidation.*
Muscle & Nerve (1998), S50

4) Shaefer J, S Jakson, **M Pourfarzam**, H Reichmann and DMT Turnbull.
*Atypical presentation of Very-Long-Chain Acyl-CoA Dehydrogenase deficiency with late onset and mild clinical presentation.*
Muscle & Nerve (1998), S196

5) Eaton S, **Pourfarzam M**, Bartlett K and Quant PA. *Beta-oxidation in neonatal cardiac mitochondria. Biochemical Society Transactions.* (1998) 26(2):S91.

6) Olpin SE, Clark S, Andresen B, Olsen RKJ, Gregersen N, Downing M, Manning NJ, Sharrard M, Bonham JR, Muntoni F, Turnbull DM, **Pourfarzam M**
*Biochemical, clinical and molecular findings in defects of mitochondrial trifunctional protein.*
J. Inher. Metab. Dis. (2004) **27**: Suppl. 1: 107.

7) Bain MD, Pourfarzam M, Turnbull D, de Sousa CM, Chalmers R.
*A brother and sister with lipid storage myopthy due to mild form of multiple Acyl-CoA Dehydrogenase deficiency*
J. Inher. Metab. Dis. (2004) **27**: Suppl. 1: 78

8) Olsen RKJ, Andresen B, Gregersen N, Miedzybrodzka ZH, **Pourfarzam** M, Merino B, Olpin SE, and Morris AAM.
*The molecular basis of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.*
J. Inher. Metab. Dis. (2005) 28, Suppl. 1: 116.

9) Leonard JV, Shortland G, Zschocke J, **Pourfarzam** M, Calvin J, Downing M, Green A, Oreton J, Andresen B, Olpin S, Dezateux
*Consensus case definition for MCADD among infant with presumptive positive newborn screening result.*
J. Inher. Metab. Dis. (2006) 29, Suppl. 1: 19.

10) Harman N. L.; Pourfarzam M.; Neely R. D. G.; Griffin, B. A.
*Plasma sterols as markers of cholesterol absorption and synthesis: inter-relationships with plasma lipids and apoE genotype*
PROCEEDINGS OF THE NUTRITION SOCIETY (2007)Volume: 66 Special Issue: SI Pages: 35A-35A

11) M Pourfarzam,
*Application of tandem mass spectrometry in clinical biochemistry: Excemplified by investigation of inherited metabolic disorders*
J Iranian Chemical Society. (2009) vol 6, suppl. S7-1

12) Morteza Pourfarzam; Gholam Basati; Saed Ziaaldin Samsamshariat,; Ahmad Movahedian; Nizal Sarrafzadegan,
*Elevated plasma platelet-activating factor acetylhydrolase enzyme activity in coronary artery disease*
11th Iranian Congress of Biochemistry, Qazvin, Iran, Feb 2011

13) Gholam Basati; Saed Ziaaldin Samsamshariat,; Ahmad Movahedian,; Morteza Pourfarzam,; Nizal Sarrafzadegan.
*Decreased plasma adiponectin levels in relation to circulating inflammatory markers in coronary artery disease*
11th Iranian Congress of Biochemistry, Qazvin, Iran, Feb 2011

14) Gholam Basati, Samsamshariat Saed Ziaaldin, Ahmad Movahedian, Morteza Pourfarzam, Nizal Sarrafzadegan
*The association of plasma leptin and homocysteine levels with the severity of coronary artery disease*
Clinical Biochemistry 44 (2011) S1

15) Amir Nader Emami Razavi, Mohsen Ani, Gholam Ali Naderi, Morteza Pourfarzam
*The relationships between HDL mean particle size and serum paraoxonase activity*
Clinical Biochemistry 44 (2011) S49

16) Amirnader Emami Razavi, Gholam Basati, Mohsen Ani, Gholamali Naderi, Morteza Pourfarzam, Maryam Boshtam
*Relationship between HDL mean size and MPO/PON1 ratio in unstable CAD patients*
Circulation Vol 125 (2012), No 19, e857

17) Morteza Pourfarzam, Gholam Basati, Ahmad Movahedian, Ziaadin Samsam Shariat, Nizal Sarrafzadegan
Association between plasma MPO and free 3-nitrotyrosine levels in patients with coronary artery disease.
13th Iranian Pharmaceutical Sciences Congress, Isfahan, Iran Sept 3-6, 2012, Iran
[i]

[i] *Last updated 1400/8/22*